Common Stock, par value $0.0001 per share
- Symbol
- LABT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Lakewood-Amedex Biotherapeutics Inc.
LABTNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On July 15, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) made available a corporate investor presentation (the “Investor Deck”) that the Company intends to use from time to time in meetings and discussions with investors, analysts, and other third parties.…
Company context
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms.
Current securities
Registered securities in this filing
Lakewood-Amedex Biotherapeutics Inc. · 8-K · Filed 2026-07-15
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01. Regulation FD Disclosure.
On July 15, 2026, Lakewood-Amedex Biotherapeutics
Inc. (the “Company”) made available a corporate investor presentation (the “Investor Deck”) that the Company intends
to use from time to time in meetings and discussions with investors, analysts, and other third parties. The Investor Deck includes, among
other things, the Company's development of Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials designed
to address drug-resistant infections and the global threat of antimicrobial resistance. It further describes the Company's lead program,
Nu-3, a topically delivered antimicrobial gel selected for clinical development for the treatment of infected diabetic foot ulcers (iDFU),
together with related preclinical and clinical data, regulatory strategy, intellectual property portfolio, competitive landscape, and
management team information.
A copy of the Investor Deck is attached hereto
as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report
on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 ea029796301ex99-1.htm LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC., INVESTOR DECK, DATED JULY 15, 2026 Exhibit 99.1 Pioneering Bisphosphocin® Compounds Advancing a novel class of fast- acting antimicrobials toaddress the global threat ofresistance 1 Forward-looking Statements This presentation may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intends," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not m e a n that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our C ompany undertakes no obligation to publicly update …
Open exhibit ↗